Certara
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and precl...
Latest News
10 days ago · seekingalpha.com
Certara, Inc. (CERT) Q3 2026 Earnings Call TranscriptCertara, Inc. ( CERT ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Jon Resnick - CEO & Director Faiz Mohammed - Interim CFO, Senior VP of Finance, Treasurer and Principal Financial & Accounting Officer Conference Call Participants Jay Liu Tucker Remmers - UBS Investment Bank, Research Division Dylan Finley - Leerink Partners LLC, Research Division David Windley - Jefferies LLC, Research Division Brendan Smith - TD Cowen, Research Division Katherine Bennorth - Morgan Stanley, Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Christine Rains - William Blair & Company L.L.C., Research Division Luke Sergott - Barclays Bank PLC, Research Division Christopher Charlton - BMO Capital Markets Equity Research Presentation Operator Good day, and thank you for standing by.
11 days ago · marketbeat.com
Certara Q3 Earnings Call HighlightsCertara NASDAQ: CERT reported 4% revenue growth in the third quarter of 2026 as double-digit software growth offset a decline in services, while cost reductions and a favorable sales mix helped lift profitability.
12 days ago · globenewswire.com
Certara Reports Third Quarter 2026 Financial ResultsCertara delivers a solid quarter with double-digit software revenue growth Updates 2026 financial outlook Appoints Grant Peterson Chief Product Officer Company to host conference call and webcast today at 8:30 a.m. ET RADNOR, Pa.
15 days ago · globenewswire.com
Birchtech Files Brief in Federal Circuit Supporting the $78 Million Patent Infringement Judgment Against CERT DefendantsBrief Details the Evidence and Law Supporting the Jury's Findings on Inducement, Contributory Infringement and Damages; Post-Judgment Interest Continues to Accrue During the Appeal CORSICANA, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Birchtech Corp. (NYSE American: BCHT) TSX: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today announced that it has filed its appellee brief with the U.S. Court of Appeals for the Federal Circuit in response to the appeal filed by the CERT defendants challenging the approximately $78 million final judgment entered in favor of Birchtech by the U.S. District Court for the District of Delaware. Birchtech filed the brief on October 22, 2026, in Birchtech Corp. v.
22 days ago · globenewswire.com
Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026RADNOR, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2026 before market open on Thursday, November 5th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.
3 months ago · seekingalpha.com
Certara, Inc. (CERT) Q2 2026 Earnings Call TranscriptCertara, Inc. (CERT) Q2 2026 Earnings Call Transcript
3 months ago · marketbeat.com
Certara Q2 Earnings Call HighlightsCertara NASDAQ: CERT reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue outlook while outlining further changes to its commercial organization, cost structure and artificial intelligence strategy.
3 months ago · zacks.com
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag EstimatesCertara, Inc. (CERT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
3 months ago · globenewswire.com
Certara Reports Second Quarter 2026 Financial ResultsAppoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its second quarter 2026 financial results.
4 months ago · globenewswire.com
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CERT